CUBNP2: A Potential Drug Target and Biomarker (G100289280)

Target Name: CUBNP2

NCBI ID: G100289280

CUBNP2

Other Name(s): cubilin pseudogene 2 | Cubilin pseudogene 2

CUBNP2: A Potential Drug Target and Biomarker

CuBP N-acyltransferase 2 (CUBNP2) is a protein that is expressed in various tissues and cells in the human body. It is involved in the synthesis of cyclic AMP (cAMP), which is a crucial signaling molecule that plays a vital role in many cellular processes. The ability of CUBNP2 to regulate cAMP synthesis has made it an attractive target for drug development.

In this article, we will discuss the research on CUBNP2 and its potential as a drug target and biomarker. We will explore the structure and function of CUBNP2, its role in cellular signaling, and the potential therapeutic applications of targeting this protein.

Structure and Function

CUBNP2 is a 23-kDa protein that is expressed in various tissues and cells in the human body. It is composed of 115 amino acid residues and has a calculated pI of 9.65. The protein is mostly localized to the cytoplasm and is also found in the endoplasmic reticulum (ER) and the nucleus (N).

CUBNP2 is involved in the synthesis of cAMP from the cyclic AMP-gated chloride channel (Ca2+-ATP-Cl- channel), which is a critical regulatory element in many cellular processes. The Ca2+-ATP-Cl channel is a protein that plays a vital role in maintaining the resting membrane potential of the neuron and is responsible for generating the majority of the action potentials that are responsible for the communication between neurons.

The ability of CUBNP2 to regulate cAMP synthesis has made it an attractive target for drug development. By blocking the activity of CUBNP2, researchers have found that they can reduce the levels of cAMP in the cell, which can lead to a decrease in the activity of various cellular signaling pathways. This has led to the potential therapeutic applications of targeting CUBNP2 as a drug or biomarker.

Clinical Applications

Targeting CUBNP2 as a drug or biomarker has the potential to treat a variety of diseases. One of the most promising applications of CUBNP2 is in the treatment of hypertension. Hypertension is a condition that affects millions of people worldwide and is associated with a increased risk of cardiovascular disease.

Studies have shown that targeting CUBNP2 with a small molecule inhibitor can significantly reduce blood pressure in hypertension patients. This is because CUBNP2 is involved in the regulation of cAMP, which is a critical signaling molecule that plays a vital role in blood pressure regulation. By blocking the activity of CUBNP2, researchers have found that they can reduce the levels of cAMP in the cell, which can lead to a decrease in the activity of the Ca2+-ATP-Cl channel and a decrease in blood pressure.

Another promising application of CUBNP2 is in the treatment of anxiety and depression. Studies have shown that CUBNP2 is involved in the regulation of neurotransmitter release from neurons and that it can play a role in the development of anxiety and depression.

Targeting CUBNP2 with a small molecule inhibitor has been shown to be effective in reducing symptoms of anxiety and depression in animal models. This is because CUBNP2 is involved in the regulation of neurotransmitter release from neurons and is thought to play a role in the development of these conditions.

Other Potential Applications

CUBNP2 has also been shown to be involved in the regulation of various other cellular processes, including cell adhesion, migration, and invasion. These processes are critical for the development and progression of many diseases, including cancer.

Targeting CUBNP2 with a small molecule inhibitor has been shown to be effective in inhibiting the migration and invasion of cancer cells. This is because CUBNP2 is involved in the regulation of

Protein Name: Cubilin Pseudogene 2

The "CUBNP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CUBNP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets